Production (Stage)
Cardiol Therapeutics Inc.
CRDL
$1.37
-$0.06-4.20%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 15.19% | -4.08% | -111.08% | 13.40% | -29.90% |
| Total Depreciation and Amortization | -61.93% | -29.53% | -18.18% | 3.91% | 6.28% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -46.81% | 447.11% | 183.15% | 40.61% | 506.87% |
| Change in Net Operating Assets | -360.00% | -37.43% | -1,349.56% | -44.40% | 99.05% |
| Cash from Operations | 2.93% | 15.91% | -123.75% | 12.44% | 30.18% |
| Capital Expenditure | -219.23% | 44.30% | -38.10% | 3.45% | 92.02% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -219.23% | 44.30% | -38.10% | 3.45% | 92.02% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.00% | 0.00% | 66.67% | 33.33% | 0.00% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -116.96% | 131,001.96% | 66.99% | 654.37% | 654.90% |
| Foreign Exchange rate Adjustments | -120.61% | 76.96% | 63.98% | -82.64% | 18,115.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -7.66% | 354.66% | -81.76% | 1.26% | 36.22% |